Clinical Trial Search

Primary: Response Rate — 1; 9.4; 12.6; 76.8 Percentage of participants

Primary: Objective Response for BAY 43-9006 in Combination With Gemcitabine and Capecitabine Evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) — 5 Participants

Primary: Proportion of Patients Alive and Progression-free at 8 Weeks — 0.70; 0.52 proportion of participants

Primary: Objective Response Rate as Measured by RECIST Criteria After Every 2 Courses of Treatment for up to 6 Courses — 2 participants

Primary: Response Rate by Solid Tumor Response Criteria (RECIST) — 16 Percentage of Participants

Primary: Number of Participants With Treatment-related Adverse Events Grade 3 or Higher as Assessed by CTCAE v4.0 — 9 Participants

Primary: Overall Survival Rate at 12 Months — 65.7 percentage of participants

Primary: Progression-free Survival at 3 Months — 2.9 months

Primary: Progression-free Survival (PFS) — 2.5 months

Primary: Dose-limiting Toxicity (DLT) (Phase I) — 1; 1 participants

Primary: Progression-free Survival (PFS) — 7.5; 7.6; 9.2; 7.4 Months — p=0.89

Primary: Feasibility as Assessed by Proportion of Patients Eligible for Intermittent Therapy Who Actually Receive it — 20 Participants

Primary: Objective Response Rate — 56.4 percentage of participants

Primary: Progression Free Survival — 9.6 months

Primary: Objective Response Rate (ORR) Evaluated Using Response Evaluation Criteria in Solid Tumors (RECIST) — 30; 25 percentage of participants

Primary: Number of Evaluable Participants With Complete Response (CR) and Partial Response (PR) at One Year — 0; 1 participants

Primary: Progression Free Survival (PFS) — 8.2; 5.6 Months — p=0.012

Primary: Central Nervous System (CNS) Response Rate by RECIST Criteria — 3; 2 participants

Primary: Incidence of Durable Stable Disease, Evaluated Using the Response Evaluation Criteria in Solid Tumors (RECIST) — 18 particip[ants

Primary: Overall Efficacy, Taking Into Account Both Objective Response and Meaningful Reductions in Tumor Burden That do Not Meet the RECIST Criteria for PR or CR (e.g., 5-30%…

Primary: Overall Objective Response Rate as Measured by RECIST — 1; 16; 6 participants

Primary: Progression Free Survival (PFS) — 5.6; 9.0; 2.8; 3.0 months — p=0.019

Primary: Tumor Burden Reduction Rate (TBRR) — 30; 70 percentage of patients

Primary: Objective Response Rate Assessed by RECIST Criteria. — 0; 3; 5; 9 participants

Primary: Progressive Free Survival (PFS) in Patients Who Receive RAD001 Plus Best Supportive Care(BSC) Versus Patients Who Receive Matching Placebo Plus BSC — 4.90; 1.87 Months

Primary: Observed Response Rate — 0; 11 percentage of patients responding

Primary: Disease-free Survival — 192; 197 Participants — p=0.737

Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 4; 10; 3; 13 participants

Primary: Proportion of Patients With Response — 0.18; 0.11 proportion of participants

Primary: Clinical Regression of Metastatic Renal Cell Carcinoma (Partial Response (PR)) or Complete Remission of Tumor (Complete Response (CR)) — 0; 0; 8; 1 participants